Insmed Revenue Beats FactSet Estimates, Stock Price Remains Uncertain

INSM reported first-quarter 2026 revenue of $306 million, exceeding FactSet estimates of $300.8 million, driven by the breakout performance of BRINSUPRI, its recently launched treatment for non-cystic fibrosis bronchiectasis. BRINSUPRI contributed $207.9 million to quarterly revenue, representing 44% sequential growth versus Q4 2025, as the company works toward its stated full-year target of at least $1 billion.

The legacy product ARIKAYCE generated $98.1 million in Q1 revenue, growing 6% year-over-year driven by strong international market performance. Combined, the two revenue streams represent a meaningful transformation from Q1 2025, when total product revenue was $92.8 million — a roughly 3.3x year-over-year increase. Net loss narrowed to $163.6 million (EPS: $(0.76)) from $256.6 million (EPS: $(1.42)) in the same quarter a year ago, reflecting operating leverage on the commercial ramp.

Despite the revenue beat, INSM shares closed down about 23% on May 7, from $137.09 to $105.00, as investors focused on guidance nuances and the company's ongoing net cash consumption during the commercial investment phase. The company maintained its full-year 2026 guidance of at least $1 billion in BRINSUPRI revenue and $450-470 million for ARIKAYCE, a combined target that analysts will watch closely as a barometer of whether the BRINSUPRI launch can sustain its momentum into the seasonally stronger second and third quarters.